These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 27415034)
1. Perspectives on investigational drugs and immunotherapies for glioblastoma. Miller JJ; Curry WT; Cahill DP; Dietrich J Expert Opin Investig Drugs; 2016 Sep; 25(9):1007-9. PubMed ID: 27415034 [No Abstract] [Full Text] [Related]
2. The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Reardon DA; Mitchell DA Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787 [TBL] [Abstract][Full Text] [Related]
3. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208 [TBL] [Abstract][Full Text] [Related]
4. Immunological challenges for peptide-based immunotherapy in glioblastoma. Mohme M; Neidert MC; Regli L; Weller M; Martin R Cancer Treat Rev; 2014 Mar; 40(2):248-58. PubMed ID: 24064197 [TBL] [Abstract][Full Text] [Related]
6. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. Maxwell R; Jackson CM; Lim M Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997 [TBL] [Abstract][Full Text] [Related]
7. Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research. Khansur E; Shah AH; Lacy K; Komotar RJ Cancer Invest; 2019; 37(1):1-7. PubMed ID: 30632816 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for secondary glioblastoma multiforme: toward an isocitrate dehydrogenase vaccine. Abecassis IJ; Morton RP; Nerva JD; Kim LJ World Neurosurg; 2014 Dec; 82(6):933-5. PubMed ID: 25311977 [No Abstract] [Full Text] [Related]
9. [Immunotherapy in brain tumors]. De Carli E; Delion M; Rousseau A Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040 [TBL] [Abstract][Full Text] [Related]